Hjem › Steatotisk leversykdom › Arkansas
Kliniske studier for Steatotisk leversykdom i Arkansas
8 studier for Steatotisk leversykdom søker deltakere på steder i Arkansas.
Byer i Arkansas
Offisiell studietekst (engelsk)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Little Rock
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Little Rock
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07701993A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Arkansas Gastroenterology - North Little Rock, North Little Rock
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Little Rock
- Akero Clinical Study Site, North Little Rock
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Arkansas Gastroenterology, P.A, Little Rock
- ARcare Center for Clinical Research, Little Rock
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06419374A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Little Rock
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07221227Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.